The newly approved 7.2 mg semaglutide injection, marketed as Wegovy HD, is intended for adults with obesity or adults who are overweight with at least one weightrelated condition, offering significantly greater weight loss than previously approved doses
The results, expected to read out later this year, could support a brand-new Alzheimers treatment for the millions of people living with this disease
Semaglutide was obtained from Novo Nordisk (Denmark)
They considered this study highly important and strongly supported it
Brain Function: L-Carnitine (specifically Acetyl-L-Carnitine) can cross the blood-brain barrier and may have neuroprotective and cognitive benefits
certified in Adult and Pediatric Obesity Management Amisa Patel, DO Board-certified in Family Medicine and Obesity Medicine Amber Patel, DO Board-certified in Family Medicine and Obesity Medicine Roberto Valledor, MD Board-certified in Family Medicine and Obesity Medicine Madeline Orack, RDN Registered Dietitian Nutritionist